This retrospective study aimed to evaluate the long-term outcomes (at least one year) for CKD and T2DM with the innovator fixed-dose combination (FDC) of empagliflozin and linagliptin in sodium-glucose cotransporter-2 inhibitor (SGLT2-i)-naïve T2DM subjects who were previously uncontrolled on a dipeptidyl-peptidase-4 inhibitor (DPP4-i)-based regimen. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.